Share on StockTwits

Shares of PTC Therapeutics (NASDAQ:PTCT) have been given a consensus recommendation of “Buy” by the eight analysts that are covering the company, ARN reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $30.87.

Shares of PTC Therapeutics (NASDAQ:PTCT) traded down 0.90% during mid-day trading on Thursday, hitting $18.63. The stock had a trading volume of 133,414 shares. PTC Therapeutics has a 52-week low of $1.563 and a 52-week high of $34.65. The stock has a 50-day moving average of $26.10 and a 200-day moving average of $22.08. The company’s market cap is $443.4 million.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.18. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $6.15 million. On average, analysts predict that PTC Therapeutics will post $-2.67 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on PTCT shares. Analysts at Zacks downgraded shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday. They now have a $19.70 price target on the stock. Separately, analysts at B. Riley initiated coverage on shares of PTC Therapeutics in a research note on Thursday, February 27th. They set a “buy” rating on the stock. Finally, analysts at Credit Suisse raised their price target on shares of PTC Therapeutics from $24.00 to $35.00 in a research note on Tuesday, February 18th.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.